Rodney Sinclair
Overview
Explore the profile of Rodney Sinclair including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
2684
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Maurer M, Ensina L, Gimenez-Arnau A, Sussman G, Hide M, Saini S, et al.
Lancet
. 2023 Nov;
403(10422):147-159.
PMID: 38008109
Background: Many patients with chronic spontaneous urticaria (CSU) do not achieve complete control of their symptoms with current available treatments. In a dose-finding phase 2b study, ligelizumab improved urticaria symptoms...
32.
Senna M, Kwon O, Piraccini B, Sinclair R, Ball S, Ding Y, et al.
Dermatol Ther (Heidelb)
. 2023 Nov;
13(12):3209-3220.
PMID: 37991697
Objectives: The present analyses report integrated results from BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) on the clinical benefits of baricitinib treatment on the basis of the amount of scalp hair regrowth...
33.
Courtney A, Triwongwarant D, Chim I, Eisman S, Sinclair R
Expert Opin Pharmacother
. 2023 Nov;
24(18):1919-1922.
PMID: 37942878
No abstract available.
34.
Wang J, White J, Sansone K, Spelman L, Sinclair R, Yang X, et al.
Clin Transl Sci
. 2023 Oct;
16(12):2614-2627.
PMID: 37849431
IL-4 and IL-13 signaling via IL-4Rα plays key roles in the pathogenesis of atopic dermatitis (AD) and asthma. Rademikibart (formerly CBP-201), a next-generation human IgG4 kappa monoclonal antibody, blocks IL-4Rα-mediated...
35.
King B, Shapiro J, Ohyama M, Egeberg A, Piraccini B, Craiglow B, et al.
Br J Dermatol
. 2023 Sep;
189(6):666-673.
PMID: 37708254
Background: Baricitinib is approved for the treatment of adults with severe alopecia areata (AA). In the absence of robust data on the patterns of regrowth during treatment of severe AA,...
36.
Wynne C, Cole A, Lemech C, Wang G, Zhang Y, Chen B, et al.
Dermatol Ther (Heidelb)
. 2023 Sep;
13(10):2357-2373.
PMID: 37668898
Introduction: Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two essential cytokines involved in the T helper 2 (Th2)-mediated inflammatory response to diseases, such as atopic dermatitis (AD). AK120 is a humanized...
37.
Asfour L, Haddad W, Bokhari L, Campbell C, Schilling S, Montgomery K, et al.
Clin Exp Dermatol
. 2023 Jul;
48(10):1190-1191.
PMID: 37405808
No abstract available.
38.
King B, Zhang X, Harcha W, Szepietowski J, Shapiro J, Lynde C, et al.
Immunotherapy
. 2023 Jul;
15(14):1093-1103.
PMID: 37403610
What Is This Summary About?: This is a summary of the results of the ALLEGRO phase 2b/3 clinical trial, originally published in . ALLEGRO-2b/3 looked at how well and safely...
39.
Sinclair R, Sharifeh S, Thackwray S, Lickliter J, Wu J, Li J, et al.
Exp Dermatol
. 2023 Jun;
32(9):1538-1545.
PMID: 37377276
Interleukin (IL)-17A underlies the pathogenesis of chronic plaque psoriasis (CPP). Well-tolerated, effective IL-17A inhibitors for mild-to-moderate CPP are needed. ZL-1102 is a novel antibody fragment targeting IL-17A. To assess the...
40.
Awad A, Nirenberg A, Sinclair R
F1000Res
. 2023 Jun;
11:945.
PMID: 37360939
Porphyria cutanea tarda (PCT) is a complex metabolic disease resulting from altered activity of the enzyme uroporphyrinogen decarboxylase (UROD) in the liver resulting in accumulation of uroporphyrin. PCT presents as...